126 related articles for article (PubMed ID: 28870907)
1. Circulating Levels of VEGF and CXCL1 Are Predictive of Metastatic Organotropismin in Patients with Colorectal Cancer.
Divella R; Daniele A; DE Luca R; Simone M; Naglieri E; Savino E; Abbate I; Gadaleta CD; Ranieri G
Anticancer Res; 2017 Sep; 37(9):4867-4871. PubMed ID: 28870907
[TBL] [Abstract][Full Text] [Related]
2. The presence of clustered circulating tumor cells (CTCs) and circulating cytokines define an aggressive phenotype in metastatic colorectal cancer.
Divella R; Daniele A; Abbate I; Bellizzi A; Savino E; Simone G; Giannone G; Giuliani F; Fazio V; Gadaleta-Caldarola G; Gadaleta CD; Lolli I; Sabbà C; Mazzocca A
Cancer Causes Control; 2014 Nov; 25(11):1531-41. PubMed ID: 25135616
[TBL] [Abstract][Full Text] [Related]
3. Circulating levels of transforming growth factor-βeta (TGF-β) and chemokine (C-X-C motif) ligand-1 (CXCL1) as predictors of distant seeding of circulating tumor cells in patients with metastatic breast cancer.
Divella R; Daniele A; Savino E; Palma F; Bellizzi A; Giotta F; Simone G; Lioce M; Quaranta M; Paradiso A; Mazzocca A
Anticancer Res; 2013 Apr; 33(4):1491-7. PubMed ID: 23564790
[TBL] [Abstract][Full Text] [Related]
4. Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients.
Carbone C; Piro G; Simionato F; Ligorio F; Cremolini C; Loupakis F; Alì G; Rossini D; Merz V; Santoro R; Zecchetto C; Zanotto M; Di Nicolantonio F; Bardelli A; Fontanini G; Tortora G; Melisi D
Clin Cancer Res; 2017 Aug; 23(15):4312-4322. PubMed ID: 28298545
[No Abstract] [Full Text] [Related]
5. Predictive impact of circulating vascular endothelial growth factor in four phase III trials evaluating bevacizumab.
Hegde PS; Jubb AM; Chen D; Li NF; Meng YG; Bernaards C; Elliott R; Scherer SJ; Chen DS
Clin Cancer Res; 2013 Feb; 19(4):929-37. PubMed ID: 23169435
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients.
Bachelot T; Ray-Coquard I; Menetrier-Caux C; Rastkha M; Duc A; Blay JY
Br J Cancer; 2003 Jun; 88(11):1721-6. PubMed ID: 12771987
[TBL] [Abstract][Full Text] [Related]
7. Circulating serum vascular endothelial growth factor is not a prognostic factor of non-small cell lung cancer.
Chakra M; Pujol JL; Lamy PJ; Bozonnat MC; Quantin X; Jacot W; Daurès JP
J Thorac Oncol; 2008 Oct; 3(10):1119-26. PubMed ID: 18827607
[TBL] [Abstract][Full Text] [Related]
8. [Serum vascular endothelial growth factor levels in patients with colorectal cancer and its prognostic significance].
Cubo T; Padilla D; de la Osa G; Palomino T; García M; Pardo R; Martín J; Arévalo E; Hernández J
Med Clin (Barc); 2004 Feb; 122(6):201-4. PubMed ID: 15012886
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of c-erbB-2 and vascular endothelial growth factor in colorectal liver metastases.
Chen J; Li Q; Wang C; Wu J; Zhao G
Ann Surg Oncol; 2010 Jun; 17(6):1555-63. PubMed ID: 20069460
[TBL] [Abstract][Full Text] [Related]
10. [Effects of chemotherapy on circulating angiogenic factor levels in patients with breast cancer].
Tang JH; Zhao JH; Gong JP; Qin JW; Pan LQ; Xu ZY
Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):210-4. PubMed ID: 17649639
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of serum angiogenic activity in colorectal cancer patients.
Gonzalez FJ; Quesada AR; Sevilla I; Baca JJ; Medina MA; Amores J; Diaz JM; Rius-Diaz F; Marques E; Alba E
J Cell Mol Med; 2007; 11(1):120-8. PubMed ID: 17367506
[TBL] [Abstract][Full Text] [Related]
12. Total and not bevacizumab-bound vascular endothelial growth factor as potential predictive factors to bevacizumab-based chemotherapy in colorectal cancer.
Azzariti A; Porcelli L; Brunetti O; Del Re M; Longo V; Nardulli P; Signorile M; Xu JM; Calabrese A; Quatrale AE; Maiello E; Lorusso V; Silvestris N
World J Gastroenterol; 2016 Jul; 22(27):6287-95. PubMed ID: 27468218
[TBL] [Abstract][Full Text] [Related]
13. Monitoring serum levels ELR+ CXC chemokines and the relationship between microvessel density and angiogenic growth factors in multiple myeloma.
Pappa CA; Tsirakis G; Kanellou P; Kaparou M; Stratinaki M; Xekalou A; Alegakis A; Boula A; Stathopoulos EN; Alexandrakis MG
Cytokine; 2011 Dec; 56(3):616-20. PubMed ID: 21940178
[TBL] [Abstract][Full Text] [Related]
14. Chemokine (C-X-C motif) ligand 1 is associated with tumor progression and poor prognosis in patients with colorectal cancer.
Zhuo C; Wu X; Li J; Hu D; Jian J; Chen C; Zheng X; Yang C
Biosci Rep; 2018 Aug; 38(4):. PubMed ID: 29784873
[TBL] [Abstract][Full Text] [Related]
15. Anti-angiogenic activity of melatonin in advanced cancer patients.
Lissoni P; Rovelli F; Malugani F; Bucovec R; Conti A; Maestroni GJ
Neuro Endocrinol Lett; 2001; 22(1):45-7. PubMed ID: 11335879
[TBL] [Abstract][Full Text] [Related]
16. Correlation of plasma level and immunohistochemical expression of vascular endothelial growth factor in patients with advanced colorectal cancer.
Minagawa N; Nakayama Y; Hirata K; Onitsuka K; Inoue Y; Nagata N; Itoh H
Anticancer Res; 2002; 22(5):2957-63. PubMed ID: 12530025
[TBL] [Abstract][Full Text] [Related]
17. CXCL1 promotes tumor growth through VEGF pathway activation and is associated with inferior survival in gastric cancer.
Wei ZW; Xia GK; Wu Y; Chen W; Xiang Z; Schwarz RE; Brekken RA; Awasthi N; He YL; Zhang CH
Cancer Lett; 2015 Apr; 359(2):335-43. PubMed ID: 25641338
[TBL] [Abstract][Full Text] [Related]
18. [The relationship between plasma level of VEGF or soluble Flt-1 and efficacy of hepatic arterial chemotherapy in patients with liver metastasis of colorectal cancer].
Gonda T; Okada N; Nakada H; Yokoyama M; Miyazaki T; Ishibashi K; Ishida H; Matsumoto Y; Miura T
Gan To Kagaku Ryoho; 2006 Nov; 33(12):1841-4. PubMed ID: 17212123
[TBL] [Abstract][Full Text] [Related]
19. Macrophage inflammatory protein-3 alpha (MIP-3a) is a novel serum prognostic marker in patients with colorectal cancer.
Iwata T; Tanaka K; Inoue Y; Toiyama Y; Hiro J; Fujikawa H; Okugawa Y; Uchida K; Mohri Y; Kusunoki M
J Surg Oncol; 2013 Feb; 107(2):160-6. PubMed ID: 22926691
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients.
Ottaiano A; Franco R; Aiello Talamanca A; Liguori G; Tatangelo F; Delrio P; Nasti G; Barletta E; Facchini G; Daniele B; Di Blasi A; Napolitano M; Ieranò C; Calemma R; Leonardi E; Albino V; De Angelis V; Falanga M; Boccia V; Capuozzo M; Parisi V; Botti G; Castello G; Vincenzo Iaffaioli R; Scala S
Clin Cancer Res; 2006 May; 12(9):2795-803. PubMed ID: 16675573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
